Cerebrospinal fluid abacavir concentrations in HIV-positive patients following once-daily administration

• Abacavir is a widely used nucleotide reverse transcriptase inhibitor, for which cerebrospinal fluid (CSF) exposure has been previously assessed in twice-daily recipients. We studied abacavir CSF concentrations in 61 and nine HIV-positive patients taking abacavir once daily and twice daily, respectively. Patients on once-daily abacavir had higher plasma and CSF concentrations (96 vs. 22ngml(-1), P = 0.038 and 123 vs. 49ngml(-1), P=0.038) but similar CSF-to-plasma ratios (0.8 vs. 0.5, P=0.500). CSF abacavir concentrations were adequate in patients receiving once-daily treatment.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Farmakologi och toxikologi (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Pharmacology and Toxicology (hsv//eng)

Nyckelord

abacavir

age

central nervous system

cerebrospinal fluid

pharmacokinetics

protease inhibitors

antiretroviral therapy

brain-barrier

plasma

drugs

pharmacokinetics

dolutegravir

combination

penetration

csf

Pharmacology & Pharmacy

Publikations- och innehållstyp

ref (ämneskategori)

art (ämneskategori)